Parimal Nathwani
Directeur Général chez Toronto Innovation Acceleration Partners
Profil
Parimal Nathwani is currently the President & Chief Executive Officer at Toronto Innovation Acceleration Partners since 2020.
He is also the Chairman at Vasomune Therapeutics, Inc. and a Director at Triphase Accelerator Corp.
Mr. Nathwani previously served as the Executive Chairman at ScarX Therapeutics, Inc. and as an Associate at Versant Partners, Inc. He holds a graduate degree from the University of British Columbia and an MBA from Simon Fraser University.
Postes actifs de Parimal Nathwani
Sociétés | Poste | Début |
---|---|---|
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada. | Président | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | Directeur Général | 01/04/2020 |
Triphase Accelerator Corp.
Triphase Accelerator Corp. BiotechnologyHealth Technology Triphase Accelerator Corp. develops oncology drug therapeutics. It engages in accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC. The firm?s product includes Marizomib which is used in cancer treatment. The company is headquartered in Toronto, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Parimal Nathwani
Sociétés | Poste | Fin |
---|---|---|
Versant Partners, Inc.
Versant Partners, Inc. Investment Banks/BrokersFinance Versant Partners, Inc. is a broker/dealer headquartered in Montreal with additional offices in Toronto and Calgary. The firm offers a full array of investment services to institutional money managers and Canadian growth companies. They cover the aerospace, biotechnology, electronics manufacturing, communications equipment and services sectors. Within those sectors, Versant Partners focuses primarily on small- and mid-sized companies. The firm executes trades on all major North American stock exchanges. They are a member of the Canadian Investor Protection Fund. | Analyst-Equity | 31/01/2009 |
ScarX Therapeutics, Inc.
ScarX Therapeutics, Inc. BiotechnologyHealth Technology ScarX Therapeutics, Inc. engages in the provision of biotechnology services. It discovers and develops innovative treatments for dermal scarring. The company was founded by Benjamin Alman in 2012 and is headquartered in Ontario, Canada. | Président | - |
Formation de Parimal Nathwani
University of British Columbia | Graduate Degree |
Simon Fraser University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 5 |
---|---|
Versant Partners, Inc.
Versant Partners, Inc. Investment Banks/BrokersFinance Versant Partners, Inc. is a broker/dealer headquartered in Montreal with additional offices in Toronto and Calgary. The firm offers a full array of investment services to institutional money managers and Canadian growth companies. They cover the aerospace, biotechnology, electronics manufacturing, communications equipment and services sectors. Within those sectors, Versant Partners focuses primarily on small- and mid-sized companies. The firm executes trades on all major North American stock exchanges. They are a member of the Canadian Investor Protection Fund. | Finance |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | Health Technology |
Triphase Accelerator Corp.
Triphase Accelerator Corp. BiotechnologyHealth Technology Triphase Accelerator Corp. develops oncology drug therapeutics. It engages in accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC. The firm?s product includes Marizomib which is used in cancer treatment. The company is headquartered in Toronto, Canada. | Health Technology |
ScarX Therapeutics, Inc.
ScarX Therapeutics, Inc. BiotechnologyHealth Technology ScarX Therapeutics, Inc. engages in the provision of biotechnology services. It discovers and develops innovative treatments for dermal scarring. The company was founded by Benjamin Alman in 2012 and is headquartered in Ontario, Canada. | Health Technology |
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada. | Health Technology |